XTSE
LABS
Market cap20mUSD
Oct 08, Last price
0.07CAD
1D
0.00%
1Q
-6.67%
IPO
-97.79%
Name
Medipharm Labs Corp
Chart & performance
P/E
—
P/S
0.66
EPS
—
Div yield, %
—
Shrs. gr., 5y
24.88%
Rev. gr., 5y
4.61%
Revenues
45m
+7.54%
Net income
-8m
L-22.69%
CFO
-6m
L+13.23%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across Canada, Australia, Germany, and other international territories. The company manages the full cycle from developing and processing to packaging and distributing a diverse array of cannabis extracts and advanced cannabinoid-based formulations. Furthermore, MediPharm Labs provides auxiliary services including GMP-certified flower procurement, specialized packaging, and comprehensive logistics. This enterprise was established in 2015 and has its corporate headquarters situated in Barrie, Canada.
Key people
Christopher Hobbs
Chief Financial Officer, Director · since 2018
Sybil Taylor
Chief Marketing Officer
Warren Everitt
Managing Director - MediPharm Labs Australia
Braden Fenske
Chief Strategy Officer · since 2019
Director · since 2019
Director · since 2018
Keith Strachan
President, Director · since 2019
Paul Tam
Director · since 2019
Headquarters & legal address
151 John Street
Barrie, ON L4N2L1
CA
Barrie, ON L4N2L1
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑09 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||